Peringatan Keamanan

There is no information regarding the lethal dosage 50 (LD50) and overdosage of crovalimab.

Crovalimab

DB16128

biotech approved investigational

Deskripsi

Crovalimab is a humanized monoclonal antibody and complement C5 inhibitor.L50908 It consists of two heavy chains (451 amino acid residues each) and two light chains (217 amino acid residues each).L50908 First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).A263958 It soon gained its approval in Japan in the next month,A263958 and in the USA in June of the same year.L50933

Unlike other complement inhibitors previously approved for PNH, crovalimab uses a mechanism called anti-C5 sequential monoclonal antibody recycling technology that allows the drug to bind to complement C5 with greater affinity and enhance C5 clearance with higher efficacy.A263953

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean estimated terminal half-life is 53.1 days.[L50908]
Volume Distribusi The mean central and peripheral volume of distribution is 3.23 L and 2.32 L, respectively.[L50908]
Klirens (Clearance) In PNH treatment-naïve patients, the mean clearance is 0.0791 L/day.[L50908]

Absorpsi

The steady-state plateau of exposure is reached approximately 12 weeks following the first intravenous loading dose.L50908 The mean (%CV) Cmax at steady-state is 292 (30.1%) µg/mL in patients greater than 40 kg but less than 100 kg, and 265 (30.9%) µg/mL in patients greater than 100 kg.L50908 The mean (%CV) area under the concentration-time curve for a dosing interval at steady state (AUC?,ss) is 7478 (30.5%) µg × day/mL in patients greater than 40 kg but less than 100 kg, and 6748 (30.7%) µg × day/mL in patients greater than 100 kg.L50908 The mean absorption rate constant is 0.126 day-1. Following subcutaneous administration, the bioavailability is 83%.L50908

Metabolisme

Crovalimab is expected to be catabolized by lysosomal proteolysis into small peptides and amino acids.L50908

Rute Eliminasi

Crovalimab is not eliminated via renal or hepatic pathways.L50908

Interaksi Obat

670 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Crovalimab.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Crovalimab.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Crovalimab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Crovalimab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Crovalimab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Crovalimab.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Crovalimab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Crovalimab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Crovalimab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Crovalimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Crovalimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crovalimab.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Crovalimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Crovalimab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Crovalimab.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Crovalimab.
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Crovalimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Crovalimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Crovalimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Crovalimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crovalimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Crovalimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crovalimab.
Cyclosporine Crovalimab may increase the immunosuppressive activities of Cyclosporine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Crovalimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Crovalimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crovalimab.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Crovalimab.
Natalizumab The risk or severity of immunosuppression can be increased when Crovalimab is combined with Natalizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Crovalimab.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Crovalimab.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Crovalimab.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Crovalimab.
Cladribine Crovalimab may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Crovalimab.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Crovalimab.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Crovalimab.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Crovalimab.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Crovalimab.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Crovalimab.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Crovalimab.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Crovalimab.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Crovalimab.
Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Crovalimab.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Crovalimab.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Crovalimab.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Crovalimab.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Crovalimab.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Crovalimab.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Crovalimab.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Crovalimab.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Crovalimab.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Crovalimab.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Crovalimab.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Crovalimab.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Crovalimab.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Crovalimab.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Crovalimab.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Crovalimab.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Crovalimab.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Crovalimab.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Crovalimab.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Crovalimab.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Crovalimab.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Crovalimab.
Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Crovalimab.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Crovalimab.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Crovalimab.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Crovalimab.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Crovalimab.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Crovalimab.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Crovalimab.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Crovalimab.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Crovalimab.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Crovalimab.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Crovalimab.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Crovalimab.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Crovalimab.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Crovalimab.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Crovalimab.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Crovalimab.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Crovalimab.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Crovalimab.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Crovalimab.
Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Crovalimab.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Crovalimab.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Crovalimab.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Crovalimab.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Crovalimab.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Crovalimab.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Crovalimab.
Tacrolimus Tacrolimus may increase the immunosuppressive activities of Crovalimab.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Crovalimab.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Crovalimab.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Crovalimab.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Crovalimab.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Crovalimab.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Crovalimab.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Crovalimab.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Crovalimab.

Target Protein

Complement C5 C5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 35699625
    Szlendak U, Budziszewska B, Spychalska J, Drozd-Sokolowska J, Patkowska E, Nowak J: Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment. Pol Arch Intern Med. 2022 Jun 29;132(6):16271. doi: 10.20452/pamw.16271. Epub 2022 Jun 6.
  • PMID: 31978221
    Roth A, Nishimura JI, Nagy Z, Gaal-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R: The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.
  • PMID: 38740735
    Dhillon S: Crovalimab: First Approval. Drugs. 2024 Jun;84(6):707-716. doi: 10.1007/s40265-024-02032-5. Epub 2024 May 14.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Piasky
    Injection, solution • 340 mg/2mL • Subcutaneous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul